157831-75-9

Usage

Uses

Used in Pharmaceutical Industry:
2-NITRO-5-PIPERIDINOPHENOL is used as a chemical intermediate for the synthesis of various drugs, leveraging its ability to inhibit tyrosine kinases, which are key in the growth and spread of cancer cells.
Used in Cancer Treatment Research:
2-NITRO-5-PIPERIDINOPHENOL is used as a research compound for studying its potential in inhibiting the enzymatic activity of tyrosine kinases, which could contribute to the development of new cancer therapies.
Used in Antibacterial and Antifungal Agents Development:
2-NITRO-5-PIPERIDINOPHENOL is used as a potential agent in the development of new antibacterial and antifungal treatments, given its demonstrated activity against these microorganisms.
Used in Safety and Hazard Management:
2-NITRO-5-PIPERIDINOPHENOL is considered in the development of safety protocols and guidelines for handling and using this chemical due to its potential to cause skin and eye irritation and respiratory problems if inhaled, ensuring the protection of workers and the environment.

InChI:InChI=1/C11H14N2O3/c14-11-8-9(4-5-10(11)13(15)16)12-6-2-1-3-7-12/h4-5,8,14H,1-3,6-7H2

Upstream product

• 110-89-4 piperidine 
• 446-36-6 5-fluoro-2-nitrophenol 

Downstream Products

• 869790-49-8 4-(1-piperidinyl)-2-(2-iodobenzyloxy)aniline 

Relevant academic research and scientific papers

Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors

Sphingolipids (SphLs) are a diverse class of molecules that are regulated by a complex network of enzymatic pathways. A disturbance in these pathways leads to lipid accumulation and initiation of several SphL-related disorders. Acid ceramidase is one of the key enzymes that regulate the metabolism of ceramides and glycosphingolipids, which are important members of the SphL family. Herein, we describe the lead optimization studies of benzoxazolone carboxamides resulting in piperidine 22m, where we demonstrated target engagement in two animal models of neuropathic lysosomal storage diseases (LSDs), Gaucher's and Krabbe's diseases. After daily intraperitoneal administration at 90 mg kg-1, 22m significantly reduced the brain levels of the toxic lipids glucosylsphingosine (GluSph) in 4L;C? mice and galactosylsphingosine (GalSph) in Twitcher mice. We believe that 22m is a lead molecule that can be further developed for the correction of severe neurological LSDs where GluSph or GalSph play a significant role in disease pathogenesis.

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site

2-Aminobenzoxazoles have been synthesized as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA. The compounds were designed to explore the less basic benzoxazole system as a replacement for the core scaffold in previously discovered benzimidazole viral translation inhibitors. Structure-activity relationships in the target binding of substituted benzoxazole ligands were investigated.

Potential Antimalarials. XX. Mannich Base Derivatives of 2--4-chloro(or 4- or 6-t-butyl or 4- or 5-fluoro)phenols and 4(or 6)-t-Butyl-2-(7-trifluoromethylquinolin-4-

Syntheses are reported for some mono- and di-Mannich base derivatives of 4-chloro-, 3- or 4-fluoro-, or 2- or 4-t-butyl-substituted 2-(7'-chloroquinolin-4'-ylamino)phenols and 2-phenols.In te